The purpose of this trial is to test if the combination of enzalutamide and metformin in
patients with castration resistant prostate cancer CRPC progressing on androgen deprivation
therapy ADT is more effective compared to enzalutamide alone. The half of the patients will
receive the experimental treatment combination, enzalutamide and metformin, while the other
half will receive enzalutamide alone.